Orloff John J
SEC-identified person · CIK 1643941 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Zenas Biopharma, Inc. ZBIO | Director | filed 2024 - 2026 |
| Alexion Pharmaceuticals, INC. alxn | EVP, Research & Development | filed 2017 - 2021 |
| QLT INC/BC QLTI | Director · See Remarks | filed 2016 - 2018 |
| Aegerion Pharmaceuticals, Inc. AEGR | EVP, Research and Development | filed 2016 - 2016 |
| Baxalta Inc BXLT | See Remarks | filed 2015 - 2016 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.